Background. Cytomegalovirus (CMV) infection or receipt of a CMV-seropositive donor liver has been shown to be an independent predictor of bacteremia in orthotopic liver transplant (OLT) recipients. However, prevention of CMV infection through use of intense CMV prophylaxis has not been examined to assess the impact on bacteremia in liver transplant recipients.
pathogen that affects organ transplant recipients [7] . CMV infection has both direct and indirect effects that impact the outcome of solid-organ transplant recipients [8] [9] [10] . With the advent of oral ganciclovir prophylaxis, we have seen a reduction in the rate of CMV infection and disease in solid-organ transplant patients, including OLT recipients [11] . Because CMV infection and the use of a transplant from a CMV-seropositive donor are significant risk factors for the development of bacteremia, and because the rates of CMV infection have decreased as a result of the use of prophylactic ganciclovir [11] , we hypothesized that ganciclovir prophylaxis is associated with a decrease in the incidence of bacteremia in OLT recipients.
METHODS

Patients
All OLT recipients who underwent transplantation during the period of 1 January 1994 through 31 Decem-ber 1999 were candidates for inclusion in this study. Patients who died р2 weeks after transplantation were excluded from the study. Patients were observed for 24 months after transplantation or until death, whichever came first. Clinical data were abstracted from an existing computerized database at Tufts-New England Medical Center (Boston, MA) and supplemented by additional chart review. Variables analyzed included CMV serological status at the time of transplantation, type of CMV prophylaxis, treatment received for rejection, intraoperative factors, blood volume use, demographic characteristics, underlying liver disease, immunosuppressive regimen, HLA match status, type of biliary anastomosis, and presence and treatment of rejection.
Outcomes
The primary outcome of our analysis was the time to development of bacteremia. Secondary outcomes included the overall rate of bacteremia, the rate of invasive fungal disease, development of CMV disease, biopsy-proven rejection, and survival at 2 years. This study was approved by the Institutional Review Committee at Tufts-New England Medical Center.
Definitions
Bacteremia. Bacteremia was defined using the description of Arbo and Snydman [12] . If different blood culture sets from the same patient (obtained up to 7 days apart) had the same isolate, they were considered to be part of a single episode. When у2 organisms were isolated from the same patient at different culture times (even when р7 days apart), each case of bacteremia was counted as a separate episode. If у2 isolates grew from the same culture set, they were counted as a polymicrobial episode of bacteremia, unless these isolates were considered to be contaminants. A contaminated blood culture was defined as any culture that grew coagulase-negative Staphylococcus species, a diphtheroid, Propionibacterium species, Bacillus species, or Micrococcus species, unless there were the following factors: 2 bottles from the same set were positive for the same organism, у2 bottles from different sets were positive for the same organism and an intravascular device was in place, or any number of bottles yielded positive results and there was an intravascular device culture yielding the same isolate, with у15 cfu in semiquantitative culture [12] .
Invasive fungal disease. Invasive fungal disease was defined as the identification of fungal or yeast species by culture or histological examination from a normally sterile site [4] . Cases of invasive fungal disease occurring after cases of bacteremia were censored for these analyses.
CMV prophylaxis. From 1994 through 1996, all OLT recipients received intravenous CMV immunoglobulin (CMVIG; 150 mg/kg every other week, for a total of 5 doses) [13] . In addition, high-risk patients (i.e., CMV-seronegative recipients of transplants from CMV-seropositive donors) received 14 days of intravenous ganciclovir (5 mg/kg q12h), and low-risk patients received oral acyclovir (3.2 g q.d.) for 120 days. From 1997 until the end of the study period, all OLT recipients received 120 days of oral ganciclovir (1 g orally t.i.d.) or the adjusted dose for their renal function. In addition, some-but not all-high-risk patients received CMVIG.
Diagnosis of CMV infection. Diagnosis of CMV-associated disease was based on laboratory and/or pathological confirmation of the presence of CMV in a patient with clinical evidence of organ dysfunction, observation of clinical resolution of disease status after initiation of ganciclovir therapy, and lack of evidence of other pathogenic processes, including infection, to explain the disease manifestations [13] . Blood buffy coat was evaluated for the presence of CMV by means of the rapid shellvial technique [14] , conventional viral culture, and/or the Hybrid Capture CMV DNA Assay, version 2.0 (Digene) [15] . Biopsy material was examined histologically for the presence of characteristic CMV-induced changes and/or was cultured by a conventional technique and/or rapid shell-vial technique.
Immunosuppression. Cyclosporine or tacrolimus were used as primary immunosuppression. Secondary immunosuppression was defined as azathioprine or mycophenolate, whichever was given at discharge from the hospital. Patients receiving OKT3 or ATG during induction or treatment for rejection were considered to have received an anti-T cell agent. Rejection episodes were uniformly treated with 3 g of intravenous methylprednisone and, if no response was achieved, with anti-T cell antibody treatment.
Rejection diagnosis. Definite liver allograft rejection was defined by histological evidence of endotheliitis with expansion of portal tracts with mononuclear cells and infiltration and swelling of bile ducts. Bile duct infiltration alone was considered to be insufficient for diagnosis. Probable rejection was defined as resolution of hyperbilirubinemia and elevated liver enzyme levels following pulse steroid treatment or anti-lymphocyte antibody treatment in the absence of a liver biopsy confirmation and of other causes.
Statistical Analysis
We compared pretransplantation, intratransplantation, and posttransplantation variables with respect to the development of bacteremia. CMV infection-related events, use of ganciclovir, and patient survival were compared between patients who did and patients who did not develop bacteremia. Comparisons of continuous variables between the 2 groups were made using Student's t test or the Kruskal-Wallis test when the data appeared to be nonnormally distributed [16] . The x 2 test and Fisher's exact test were use to compare the distributions of categorical variables between groups [16] . Cox proportional hazards survival models were used to model univariate rela- , by the log-rank test. P p .02 tionships of pretransplantation, intratransplantation, and posttransplantation events with time to first episode of bacteremia [17] . Events that occurred after bacteremia were censored. For these analyses, posttransplantation events were modeled as time-dependent covariates to account for the timing of their onset. Because of the small number of outcomes (29 patients had у1 occurrence of bacteremia), we restricted multivariable model-building to exploring models containing р3 predictor variables. Shoenfeld residuals were evaluated to check that the assumption of proportional hazards was reasonable for the final multivariable analysis presented in this article. Kaplan-Meier curves were generated to display bacteremia-free survival over the 2-year follow-up period and were stratified by the CMV infection status of the donor and whether ganciclovir was received [18] . Analyses were done using the SAS system for Windows, version 8.2 (SAS Institute), and S-Plus, version 6.1 for Windows (Insightful).
RESULTS
During the study period, 201 OLT recipients were identified. Nine patients died р2 weeks after transplantation and were excluded from the study. A total of 59 episodes of bacteremia were observed in 29 (15%) of the 192 patients. The isolates identified were Enterococcus species (18 isolates), coagulasenegative staphylococci (15 isolates), Klebsiella pneumoniae (11 isolates), Escherichia coli (4 isolates), and Staphylococcus aureus (6 isolates), as well as Pseudomonas species (2 isolates), Leuconostoc species (2 isolates), Clostridium species (1 isolate), and Klebsiella oxytoca (1 isolate).
Factors associated with bacteremia. By examining the population using survival curves stratified by CMV donor status and duration of ganciclovir treatment, we demonstrated a lower likelihood of bacteremia over time in patients receiving у14 days of ganciclovir treatment, compared with patients who received !14 days of treatment, regardless of the CMV status of the donor ( ) ( figure 1 ). P p .02 Examination of patients based on the presence or absence of bacteremia showed that у14 days of ganciclovir use was more common in the group of patients without bacteremia ( ) (table 1) . "Any" duration of ganciclovir treatment P p .0193 and the use of "any" amount of CMVIG did not differ between the groups ( ) (table 1) . Patients with and patients with-P 1 .05 out bacteremia were not different when analyzed on the basis of age, sex, immunosuppressant regimen at the time of discharge, and CMV infection status of donors and recipients ( ) (table 1) . The group without bacteremia included a P 1 .05 higher proportion of patients with primary biliary cirrhosis and hepatitis C virus infection ( ) as their underlying com-P p .043 orbidities. The group with bacteremia included a higher proportion of patients who had primary sclerosing cholangitis, as well as greater use of anti-lymphocyte products ( ). P p .0011 Among the factors known to be associated with bacteremia, we found that patients with bacteremia received a higher median number of units of packed RBCs ( ) and of fresh P p .0029 frozen plasma ( ). Choledochocholedochostomy was P p .029 more common in the group without bacteremia ( ) P p .0102 (table 1) . The 2-year mortality rate was significantly different between the group with bacteremia (26.9%) and the group without bacteremia (9.3%; ) (table 1) . P p .0112 Using Cox proportional hazard models, treatment with у14 ), receipt of treatment P p .0033 for rejection (HR, 2.36; 95% CI, 1.08-5.14;
), and P p .0308 solumedrol use (HR, 2.58; 95% CI, 1.18-5.62; ) were P p .0170 significantly associated with the development of bacteremia (table 2) .
Multivariate analysis. We used multivariable Cox proportional hazards regression models to control for potential confounding between the known risk factors for bacteremia and the use of ganciclovir. To assess the independence of the ganciclovir association, we performed several 3-variable analyses controlling for different combinations of known factors associated with bacteremia (large volume of transfusions, invasive fungal disease, treatment for rejection, use of solumedrol or anti-lymphocyte products, and choledochocholedochostomy), with у14 days of ganciclovir. Because of the small number of outcomes of our study ( ), we limited our final n p 29 analysis to a 3-variable model. When we controlled for choledochocholedochostomy and use of !10 U of RBCs, use of у14 days of ganciclovir was still associated with a reduced risk of bacteremia (HR, 0.44; 95% CI, 0.20-0.98; ) (table P p .0437 3). We performed additional 3-model analyses with combinations of у14 days of ganciclovir and choledochocholedochostomy, invasive fungal disease, use of solumedrol, or treatment for rejection. Regardless of the combination analyzed, there was a consistent association between the use of у14 days of ganciclovir and the prevention of bacteremia. In all of our models, we found similar adjusted HRs for the association between receipt of у14 days of ganciclovir and prevention of bacteremia (data not shown).
DISCUSSION
There are several reports that establish an association between the receipt of a liver transplant from a CMV-seropositive donor or CMV infection and the development of bacteremia in OLT recipients [1, 6] . However, to our knowledge, there have been no studies to date that have linked the use of prophylactic ganciclovir to a reduction in the rate of bacteremia.
Because ganciclovir prophylaxis constitutes the current standard of care at our institution, we decided to look at time periods both before and after 1997 for patients who either were not exposed to or had limited exposure to ganciclovir. Univariate analyses of ganciclovir use were performed using survival analysis, taking into account the timing of bacteremia. These analyses showed that the use of ganciclovir in general is associated with prevention of bacteremia. We chose to use the cutoff of у14 days of treatment for most of our analyses to maximize the power of these comparisons, because approximately one-half of the subjects fell into each of these treatment groups. Using survival plots, we were able to show that use of у14 days of ganciclovir, regardless of the CMV infection status of the liver transplant donor, was associated with fewer episodes of bacteremia ( ). The impact of ganciclovir use was P p .02 predominantly seen in the group of patients receiving CMVseropositive donor organs. This is consistent with the hypothesis that one would expect, because receipt of a transplanted organ from a CMV-positive donor is associated with a greater risk of bacteremia, presumably through transmission of latent CMV infection from the donor organ. Therefore, use of ganciclovir, with reduction in CMV expression in the host, would be expected to have its greatest impact in this group.
For descriptive purposes, we divided our subjects into groups on the basis of whether they developed bacteremia. As seen in table 1, receipt of у14 days of ganciclovir prophylaxis was more common in the group without bacteremia ( ). Al-P p .0193 though the use of any amount of ganciclovir did not differ between the 2 groups, there was a trend towards a reduction in the incidence of bacteremia ( ). P p .06 Additional univariate analysis with known factors associated with the development of bacteremia-namely, CMV infection, Roux-en-Y anastomosis, invasive fungal disease, transfusion of a large volume of blood products, treatment for rejection, antilymphocyte products, and use of solumedrol for rejectionhad HRs for an association with bacteremia that were concordant with published literature, thus validating our own data set. Although, CMV-seropositive donor status per se failed to show an increase in the rate of bacteremia, we hypothesize that the failure was a result of the confounding effect of ganciclovir treatment that was not controlled for in this univariate model. In fact, examination of survival curves shows that, in absence of ganciclovir therapy, the receipt of a transplant from a CMVseropositive donor yielded the highest risk of bacteremia, confirming our earlier published data.
To assess the independence of the ganciclovir association, we performed 3-variable analyses controlling for different combinations of known factors associated with bacteremia (large volume of transfusions, invasive fungal disease, treatment for rejection, use of solumedrol, use of anti-lymphocyte products, and choledochocholedochostomy), with у14 days of ganciclovir therapy. Regardless of the combination analyzed, there was a consistent association between the use of у14 days of ganciclovir and the prevention of bacteremia.
Because improvement in surgical technique over time could potentially explain a decrease in the incidence of bacteremia, we stratified our cases by year of transplantation (data not shown). We found that earlier transplantations (1994) (1995) (1996) were associated with an incidence of bacteremia of ∼20% per 2-year period after transplantation, compared with 10% in the later period (1997) (1998) (1999) . The change in the incidence of bacteremia happened between 1996 and 1997, which coincides with the onset of ganciclovir prophylaxis in all patients. If this change were due to improved surgical techniques, we would have expected a continuous improvement in freedom from bacteremia rather than an abrupt change. Furthermore, when we explored models that include volume of blood transfused, which may serve as a proxy for both severity of illness and surgical technical improvements, we find that the HR for reduction in the incidence of bacteremia with у14 days of ganciclovir prophylaxis did not change and remained significant, thus supporting our hypothesis.
Identifying risk factors associated with bacteremia is important because of the impact that bacteremia has on the mortality rate among OLT recipients. In some studies, bacteremia can increase the mortality rate among OLT recipients by up to 3-fold [19] . In our study, we found a significant difference in the mortality rate between patients with bacteremia (26.9%) and those without bacteremia (9.3%) ( ). P p .0112 We found strong associations with factors known to be associated with bacteremia after receipt of an OLT, despite the retrospective cohort study design, which could potentially have resulted in missing data. Also, with the use of 3-variable analyses, we found a persistent association between у14 days of ganciclovir use and the development of bacteremia, regardless of which factors were controlled, further strengthening the conclusions of our study.
We conclude that the use of ganciclovir as the standard of care for liver transplant recipients, regardless of their CMV infection status, reduces the rate of bacteremia. Such use should be cost-effective in the long term, in part by resulting in a reduction in the morbidity and mortality associated with bacteremia.
